Orelabrutinib (a Bruton's tyrosine kinase [BTK] inhibitor) should not be used in combination with strong CYP3A inhibitors/inducers, anticoagulants/antiplatelet agents, immunosuppressants, etc. Specifically, dosage adjustments should be made under the guidance of a physician. The drug is primarily metabolized by the CYP3A enzyme system, and co-administration with other drugs may affect its efficacy or increase the risk of toxic reactions.
Drug Classes Requiring Cautious Co-administration
Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)
Co-administration may elevate orelabrutinib plasma drug concentration, thereby increasing the risk of adverse reactions such as infection and bleeding.
Strong CYP3A inducers (e.g., rifampicin, phenytoin sodium, carbamazepine)
Co-administration may reduce the efficacy of orelabrutinib and impair disease control.
Anticoagulants/antiplatelet agents (e.g., warfarin, aspirin, clopidogrel)
Co-administration may heighten bleeding risk, necessitating close monitoring of coagulation function.
Immunosuppressants (e.g., cyclosporine, tacrolimus)
Co-administration may exacerbate immunosuppression, increasing susceptibility to infection or myelosuppression.
Additional Precautions
Avoid grapefruit and its products, as they may inhibit CYP3A enzymes and interfere with drug metabolism.
Exercise caution when using over-the-counter (OTC) drugs and Chinese herbal medicines, such as St. John's Wort (a CYP3A inducer) and certain antipyretic and analgesic agents (e.g., ibuprofen), which may trigger drug interactions.
Medication Guidelines
Inform your physician of all current medications, including prescription drugs, OTC drugs, and dietary supplements.
Adjust dosage under medical supervision: If co-administration with interacting drugs is unavoidable, physicians may adjust the dosage of orelabrutinib or conduct regular monitoring of relevant indicators based on individual patient conditions.
Seek immediate medical attention if any abnormalities occur, such as unexplained bleeding, signs of infection (e.g., fever, cough), or severe diarrhea.
Orelabrutinib is a prescription medication. Treatment regimens must be formulated by specialists based on the patient’s individual circumstances. Do not co-administer or discontinue any medications without medical approval.
